442 related articles for article (PubMed ID: 26836793)
1. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
Hansen PS; Sanchez R; Walfridsson H
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
[TBL] [Abstract][Full Text] [Related]
2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
3. The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
Koektuerk B; Turan CH; Yorgun H; Keskin K; Schoett M; Dahmen A; Gorr E; Yang A; Hoppe C; Horlitz M; Turan RG
Cardiovasc Ther; 2016 Jun; 34(3):144-51. PubMed ID: 26880220
[TBL] [Abstract][Full Text] [Related]
4. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
[TBL] [Abstract][Full Text] [Related]
6. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
Zhang RF; Ma CM; Wang N; Yang MH; Li WW; Yin XM; Dong YX; Yu XH; Xiao XJ; Xia YL; Gao LJ
BMC Cardiovasc Disord; 2021 Apr; 21(1):214. PubMed ID: 33906609
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
[TBL] [Abstract][Full Text] [Related]
8. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
11. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
[TBL] [Abstract][Full Text] [Related]
14. Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Vedovati MC; Verdecchia P; Giustozzi M; Molini G; Conti S; Pierpaoli L; Valecchi F; Aita A; Agnelli G; Becattini C
Int J Cardiol; 2017 Jun; 236():363-369. PubMed ID: 28131705
[TBL] [Abstract][Full Text] [Related]
15. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
[TBL] [Abstract][Full Text] [Related]
17. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
[TBL] [Abstract][Full Text] [Related]
18. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Coleman CM; Khalaf S; Mould S; Wazni O; Kanj M; Saliba W; Cantillon D
Pacing Clin Electrophysiol; 2015 Jun; 38(6):731-7. PubMed ID: 25721150
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.
Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A
Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
